Engineered Lymphocyte Manufacturing for High-Purity TSCM CAR-T

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating genetically engineered T cells with high purity of T memory stem cell (TSCM) subset are unpredictable due to variations between donors and patients, and bead-based processes are not compatible with complex T subset isolation, leading to inconsistent clinical outcomes.

Innovation Solution

A method is developed to isolate CD45RA and CCR7 double-positive T cells by depleting CD45RO-positive cells and enriching for CD4 and CD8 T cells, resulting in a final CAR-T cell population with high purity of TSCM subset (>90%) and improved product profile.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If bead-based process is used for clinical scale processing of leukapheresis, then processing capacity is improved, but compatibility with complex T subset isolation is lost

Engineering Contradiction:

Improveprocessing capacityVSAvoidcompatibility with complex T subset isolation

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and removes CD45RO-positive cells from the leukapheresis product using immunomagnetic depletion technology. This extraction approach allows the bead-based process to specifically target and remove unwanted cell subsets while preserving the desired TSCM cells, thereby maintaining processing capacity while achieving complex T subset isolation.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the approach from positive enrichment to negative selection by depleting CD45RO-positive cells. This parameter change in the isolation strategy allows the use of bead-based technology for clinical scale processing while achieving the desired T subset isolation, as the depletion method is compatible with high-throughput bead-based platforms.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If multiple steps of positive enrichment are used for T subset isolation, then isolation precision is improved, but process complexity increases

Engineering Contradiction:

Improveisolation precisionVSAvoidprocess complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent inverts the traditional approach by using negative selection (depletion of CD45RO-positive cells) instead of positive enrichment. This inversion simplifies the process from multiple steps of positive enrichment to a single depletion step followed by expansion, reducing process complexity while maintaining high isolation precision for TSCM cells.

Inventive Principle:

Principle #13The other way round (Inversion)

3Ease of manufacture

If donor variations are not accounted for, then process simplicity is maintained, but product consistency deteriorates

Engineering Contradiction:

Improveprocess simplicityVSAvoidproduct consistency

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent performs preliminary depletion of CD45RO-positive cells from the leukapheresis product before T cell expansion. This preliminary action removes the source of variability associated with donor differences in T subset distribution, ensuring that the starting material for expansion has a consistent and controlled TSCM cell content, thereby improving product consistency without significantly complicating the manufacturing process.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250297219A1Methods for generating engineered lymphocytes with enriched t memory stem cells

Publication Date: 2025.09.25 KITE PHARMA INC

AI summary

Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.